当前位置: 首页 > 详情页

Chinese Consensus Statement on the Evaluation and Intervention of Collateral Circulation for Ischemic Stroke

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing 100050, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Stroke Ctr, Beijing 100050, Peoples R China; [3]Jinan Univ Guangzhou, Affiliated Hosp 1, Dept Neurol, Guangzhou, Guangdong, Peoples R China; [4]Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [5]Univ Illinois, Coll Med Peoria, OSF INI Comprehens Stroke Ctr, Dept Neurol, Peoria, IL USA; [6]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, 6 Tiantan Xili, Beijing 100050, Peoples R China
出处:
ISSN:

关键词: Evaluation Ischemic stroke Intervention Consensus Collateral circulation

摘要:
Background Collateral circulation is becoming more significant in the individual management strategy of ischemic stroke, there are more data updated recently. Aim To make the further acknowledgment of the evaluation and how to improving collateral flow, for better treatment selection. Method A panel of experts on stroke providing related statement based on review the results from most up-to-date clinical research. Results DSA is the gold standard in evaluating all levels of collaterals. CTA can be used for evaluating leptomeningeal collaterals, MRA for CoW, TCD or TCCS can be used as screening tool for primary evaluation. The treatment modalities include direct interventions, such as Extracranial-Intracranial bypass, and indirect interventions, as External counterpulsation and pressor therapy. The consideration of methodology to augment and improve can be considered on an individual basis. Discussion In this consensus, we interpret the definition, neuroimaging evaluation, intervention and potential strategy on collaterals in the future. Conclusion Assessment of collateral circulation is crucial for selecting therapeutic options, predicting infarction volume and making prognosis after ischemic stroke. Data is still needed to provide therapeutic evidence for many new developed technologies. Until more evidence is available, the clinical significance of applying the new technologies is unclear and perhaps limited.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 神经科学
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 神经科学 2 区 药学
JCR分区:
出版当年[2012]版:
Q1 NEUROSCIENCES Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q1 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing 100050, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Stroke Ctr, Beijing 100050, Peoples R China;
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing 100050, Peoples R China; [2]Capital Med Univ, Beijing Tiantan Hosp, Stroke Ctr, Beijing 100050, Peoples R China; [6]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, 6 Tiantan Xili, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院